NASDAQ : VKTX
Viking Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 26.86 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.43B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.44B |
| Enterprise Value | 2.73B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 127.52M |
| Shares Outstanding | 127.52M |
| Shares Change (YoY) | +3.55% |
| Shares Change (QoQ) | +1.54% |
| Owned by Insiders (%) | 2.25% |
| Owned by Institutions (%) | 60.36% |
| Float | 124.60M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.91 |
| P/TBV Ratio | 5.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.27 |
| Quick Ratio | 7.17 |
| Debt / Equity | 0.43 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7,370.14 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -96.37% |
| Return on Assets (ROA) | -47.23% |
| Return on Invested Capital (ROIC) | -52.07% |
| Return on Capital Employed (ROCE) | -76.91% |
| Weighted Average Cost of Capital (WACC) | 7.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$9.65M |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.65 |
| 52-Week Price Change | -28.28% |
| 50-Day Moving Average | 30.38 |
| 200-Day Moving Average | 32.38 |
| Relative Strength Index (RSI) | 48.09 |
| Average Volume (20 Days) | 4,860,433 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 25.54M |
| Short Previous Month | 25.92M |
| Short % of Shares Out | 20.03% |
| Short % of Float | 20.50% |
| Short Ratio (days to cover) | 2.88 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -648.57M |
| Pretax Income | -627.20M |
| Net Income | -627.20M |
| EBITDA | n/a |
| EBIT | -648.57M |
| Earnings Per Share (EPS) | -$5.41 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 959.81M |
| Total Debt | 254.69M |
| Net Cash | 705.12M |
| Net Cash Per Share | $5.53 |
| Equity (Book Value) | 588.60M |
| Book Value Per Share | 4.62 |
| Working Capital | 839.10M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -462.63M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 494,000 |
| Net Borrowing | 251.00M |
| Free Cash Flow | -462.63M |
| FCF Per Share | -$3.63 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.55% |
| Shareholder Yield | -3.55% |
| Earnings Yield | -20.07% |
| FCF Yield | -13.30% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $95.32 |
| Price Target Difference | 253.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |